Aim of the study: Pregnane glycosides are potent cytotoxic agents which may represent new leads in the development of anti-tumour drugs, particularly in the treatment of breast cancer, because of the structural similarity to estrogenic agonists. Caralluma species are natural sources of a wide variety of pregnane glycosides. The aim of the study was to isolate, using an activity-guided fractionation approach, novel pregnane glycosides for testing on breast cancer and other tumour lines.
Introduction
Caralluma tuberculata (N.E.Brown) a member of the Asclepiadaceae family, is a succulent, perennial herb growing in the wild in Pakistan and India (Andra Pradesh), United Arab Emirates, Saudia Arabia, the south east of Egypt (Tackholm et al, 1974; Baquar et al, 1989) , and other countries. In the literature, the plant has also been reported as Boucerosia aucheriana (Ali et al, 1983) .
The roots of Caralluma tuberculata are eaten raw, or cooked as a vegetable, (Ali et al 1983 , Ahmad et al 1988 , and the plant is traditionally used for its anti-inflammatory and anti-tumour properties (Ahmad et al 1983 (Ahmad et al , 1988 Ahmed et al 1993 , Copra et al 1956 , Mahmood et al 2010 . Several pregnane glycosides isolated from organic extracts of Caralluma tuberculata showed cytotoxicity against the MRC5 human diploid embryonic cell line (Abdel-Sattar et al 2008 . Pregnanes are C 21 steroids and often found in nature conjugated as glycosides. Caralluma and other members of the Asclepiadaceae family are rich in esterified polyhydroxypregnane glycosides, which have potentially important anti-cancer and anti-tumour effects (Deepak et al. 1989 (Deepak et al. , 1997 Gupta et al 2003) , and may provide interesting leads for the development of new drugs.
The aim of the present study was to isolate novel pregnane and related steroids from Caralluma tuberculata and to elucidate their structures and cytotoxicity. The next step was to use an activityguided fractionation approach to identify those organic fractions of Caralluma tuberculata with the highest anti-proliferative activity against MCF-7 human breast cancer cells and Caco-2 human colon cells using the MTT and neutral red uptake assays. Following identification of any compounds isolated in the most active fractions, the cytotoxicity of these compounds would then be tested on the cell lines and the mode of cell death investigated using established assays of apoptosis and necrosis.
Materials and Methods

Plant material
Caralluma tuberculata was collected from the surrounding areas of Mansehra Valley, Pakistan in February 2007, and identified by Dr. Manzoor Hussain, Department of Botany, Hazara University, Mansehra, Pakistan. A voucher specimen (HU-2761A-07) was deposited at the Herbarium of Department of Botany, Hazara University, Mansehra, Pakistan.
Extraction and Fractionation
The whole fresh plant (10 kg) was air-dried, powdered and macerated in EtOH (3 x 1000 ml) at room temperature for 7 days. The extract was filtered under vacuum and evaporated under reduced pressure at 40 o C. This yielded a semi-solid residue, dark greenish in colour (200 g). The concentrated extract was dispersed in H 2 O (1000 ml), partitioned into four organic fractions starting with hexane (3 x 300 ml), CHCl 3 (3 x 500 ml) and EtOAc (3 x 500 ml) respectively. The MeOH fraction (3 x 300 ml) was separated from the insoluble residue after evaporating the remaining aqueous layer. This procedure resulted in hexane fraction (5 g), CHCl 3 fraction (8 g), EtOAc fraction (20 g), MeOH fraction (22g) and aqueous fraction (28 g).
Isolation of compounds
The EtOAc fraction was loaded (12 g) on silica gel 60 (2 kg) for column (100 cm x 12 cm) adsorption chromatography packed in CHCl 3 . Stepwise elution was carried out using CHCl 3 -MeOH gradient solvent system (1:0, 20:1, 10:1, 8:1, 5:1, 3:1, 2:1, and 0:1; 2.0 L for each step). Fractions of 200 ml were collected and concentrated; TLC was carried out for all the eluted fractions and visualised under UV illumination (254nm). Fractions possessing similar R f values were combined together and this resulted in 25 major fractions. Fraction 18 (352 mg) showed a mixture of two compounds on TLC. The fraction was chromatographed on a silica gel column (500 g, 3.5 cm x 60 cm) and eluted with EtOAc-MeOH Column Chromatography was purchased from Fluka Analytical, Switzerland. To determine the steroidal nature of the compounds, the EtOAc fraction and isolated Compounds 1 and 2 were analysed by Liebermann-Burchard test (Burke et al., 1974; Halim & Khalil 1996) . Melting points were determined on a Gallenkamp (Sanyo) melting point instrument and are uncorrected. Optical rotations were measured in MeOH solutions with a Optical Activity AA-10 automatic polarimeter. FT-IR Spectra were recorded on PerkinElmer Spectrum 100FT-IR spectrometer with Spectrum Express sodium chloride discs. and gentamycin (40 μg/ml), penicillin (100 units/ml) and streptomycin (1040 μg/ml). HUVEC (human umbilical vein endothelial cells) were isolated from umbilical cords (kindly donated by Dr Anshuman Ghosh, School of Life Sciences, Kingston University, UK) by enzymatic detachment using collagenase, as previously described (Bernhard et al., 2003) . HUVEC Cells were routinely passaged in 0. All cell lines were grown in a humidified incubator at 37 o C in an atmosphere containing 5% CO 2 and were in the logarithmic phase of growth at the time of cytotoxicity assays. Cells were harvested and seeded into 96-well tissue culture plates at a density of 1x10 4 cells per well in 200 l aliquots of medium. The cells were allowed to attach for 24 h at 37°C, 5% CO 2 in air in a humidified atmosphere.
NMR and mass spectrometry (MS) analysis
The next day, the plant extract in serial dilution or desired final concentration of organic fraction and isolated glycosides dissolved in DMSO (maximum: 0.01%) were added to the desired final concentrations and after a 24 h exposure period, the toxic endpoints were determined. Control groups received the same amount of DMSO. Actinomycin-D (4μM), tamoxifen (5μM) and anastrozole (5μM) were used as positive controls in 200μl media as a final concentration in the well.
Neutral red assay
According to the Borenfreund & Puerner (1985) Acorn House, East Sussex, UK) within 60 minutes.
MTT assay
According to method described by Borenfreund et al. (1988) growth of cancer cells was quantified by the ability of mitochondrial succinic dehydrogenase enzyme in the living cells to reduce the yellow dye 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) to a blue insoluble product formazan. Following a 24 h exposure period of drugs, cells were washed twice with PBS, and a 10 μl/well of MTT reagent (5 mg/ml in PBS) was added. The plates were returned to the incubator for 4 h.
Subsequently, cells were washed twice with PBS, and 100 μl/well DMSO was added as solvent to dissolve the insoluble crystalline formazan products. Drug effect was quantified as the percentage of control absorbance of reduced dye at 550 nm.
Cytomorphological alterations (DAPI staining)
The nuclear stain DAPI was used to assess morphological changes in nuclei of treated cells. Cells were seeded at 1x10 4 cells/well in 500μl of DMEM on sterilised glass coverslips in 12 well plates for 24 h. secondary antibody (Anti-rabbit IgG from Donkey, product code NA 9340, Amersham Biosciences, UK) in 1% Milk in TBS-T (10 ml) for 2h. After extensive washing with TBS-T for 2 h, bands were detected by ECL reagent. Band intensities were quantified using the ECL system on X-ray film (GE Healthcare, UK).
DNA fragmentation (ladder) assay
DNA fragmentation assay was conducted using the procedure of Wu et al. (2005) and Gilbert et al., EDTA, pH 8), supplemented with 5μl of GelRed (Biotium Hayward, UK). The solid gel was placed in a tank containing 1× TAE buffer. Isolated DNA was injected into the wells formed after solidification starting with Amplisize molecular marker (50-2,000bp, Cat. 170-8200, Bio-Rad, UK) and 100V current applied for 45 min. After electrophoresis the gel was visualised using the GelDoc system and was photographed through digital camera. 
Materials
Data presentation and statistical analysis
All data were compiled from a minimum of three experiments. Data for statistical analysis were expressed as the mean + standard deviation, n (number of experiments). One-way ANOVA with Dunnett's or Tukey's post test, as specified, was performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA.
Results
Activity of the crude extract
A series of eight dilutions of Caralluma tuberculata crude extract (10 -500 μg/ml) were used to determine the concentration-dependent, anti-proliferative effect on three cancer cell lines (MCF-7, MDA-MB-468, Caco-2). The data indicated significant concentration-dependent growth inhibition of the malignant cells after 24 hours with an apparent IC 50 value of about 100 μg/ml (n=3) with the neutral red uptake (NRU) assay (Figure 1 ). Similar results were obtained with the MTT assay, where the IC 50 value was about 200 μg/ml (data not shown).
Figure 1. Treatment of cells for 24 hours with the crude extract of Caralluma tuberculata over a range of concentrations. Cell growth was measured using the NRU assay.
Activity of organic fractions
In a biologically activity-guided fractionation approach, the hexane, CHCl 3 EtOAc, MeOH and aqueous fractions of Caralluma tuberculata were evaluated at a concentration of 200 μg/ml against MCF-7, MDA-MB-468 and Caco-2 cells. The anti-proliferative activity was significantly concentrated in three fractions (CHCl 3 , EtOAc and MeOH, n=3 for each fraction, mean ± sd) with similar results obtained with the NRU assay (Figure 2 ). The EtOAc fraction had the maximum effect on the cells, reducing growth by 94% ± 4.0 % (n=3) on MCF-7 cells, and 96% ± 7.7% on Caco-2 cells, using the NRU assay.
Again, similar results were obtained with the MTT assay: 95% ± 2.6 % inhibition on MCF-7 cells (n=3) and 93% ± 3.9 % inhibition on Caco-2 cells (n=3) (data not shown). MDA-MB-468 cells were less sensitive to each of the fractions, with the ETOAc fraction still the most active, but with only 46% ± 2.8% (n=3) inhibition (NRU assay, Figure 2) , and 39% ± 6.4% (n=3) inhibition (MTT assay, data not shown).
Figure 2. Treatment of cancer cells for 48 hours with specific organic fractions of Caralluma
tuberculata at 200 g/ml. Cell growth was measured using the NRU assay.
Characterisation of pregnane and androstan glycosides
Compound 1 was isolated as a light-yellowish white, amorphous powder and identified by MS, GC-MS, IR and NMR data as an acylated pregnane glycoside with the molecular formula C 48 H 72 O 20 . Therefore, based on the present studies and reported data, the structure of Compound 1 was established as 12-O- (Fig. 3) .
Compound 2 was also isolated as a light greenish-white, amorphous powder and identified as an acylated androstan glycoside with the molecular formula C 68 H 106 O 26 , as deduced from 1 H, 13 C, DEPT, edited DEPT NMR and ESI-MS (positive). The structure of Compound 2 was established as 7-O-acetyl- (Fig.3) . (NRU assay) after 48 hours. Tamoxifen completed inhibited the growth of MCF-7 after 48 hours, using either MTT or NRU assay, but was less effective, as expected, on the growth of MDA-MB-468 cells (45% MTT assay, 63% NRU assay). Anastrozole was only moderately inhibitory on MCF-7 cells (46% MTT assay, 36% NRU assay) but much more effective on MDA-MB-468 cells (87% MTT assay, 93%
MRU assay).
Figure 5. Treatment of cancer cells for 48 hours androstan glycoside over a concentration range. Cell growth was measured using the NRU assay.
Further experiments were performed to investigate the mode of action of the pregnane glycosides on cells, for example, did compounds 1 and 2 stimulate apoptosis or necrosis, and was the activation of caspases In the first experiment, cells received either glycoside at the IC 50 concentration for 12 hours: pregnane glycoside MCF-7 20 M, MDA-MB-468 50 M, Caco-2 10 M; androstan glycoside MCF7 12.5 M,
MDA-MB-468 50 M, Caco-2 6.25 M. Cells were then stained with the blue nuclear dye DAPI and visualised on a confocal microscope (see Methods). In the case of the MCF-7 and Caco-2 cells, addition of the pregnane or androstan glycoside resulted in shrinkage of cells, a reduction in cell number and evidence of nuclear fragmentation, all characteristics of apoptosis, when compared to untreated cells or cells treated with vehicle (0.01% DMSO) (Figure 6 ). MDA-MB-468 cells, however, appeared fewer in number, after treatment with the steroidal glycosides, but those remaining cells appeared a little larger than untreated or vehicle-treated cells, suggesting swelling characteristic of necrosis. Figure 6 . Treatment of cancer cells for 24 hours with vehicle (0.01% DMSO) and pregnane or androstan glycosides at the IC 50 concentration for the specific cell type with positive control as Actionmycin -D. Cell nuclei were stained with DAPI where: , In the second experiment, the involvement of caspases was assessed by use of the pan-caspase inhibitor Z-VAD-FMK (50μM). Cells were treated as follows for 24 hours with pregnane glycoside at its IC 50 value depending on cell type: MCF-7 20μM, MDA 50μM, Caco-2 10μM, and similarly for androstan glycoside: MCF-7 12.5μM, MDA-MB-468 50μM, Caco-2 6.25μM. In all cases the inhibition in growth by the novel steroidal glycosides was reduced by pre-treatment with Z-VAD-FMK, as was the effect of actinomycin-D (Figure 7 , MCF-7 cells shown, very similar results were obtained for MDA-MB-468 and Caco-2 cells, data not shown). Vehicle had no effect on cell growth, but Z-VAD-FMK had a slight stimulatory effect, perhaps as a consequence of inhibiting a sub-population of untreated cells in apoptosis.
All treatments, including those with Z-VAD-FMK, were statistically significant to vehicle-treated controls (one way ANOVA with Tukey's post-test). In the third experiment, we used Western blots to detect cleaved PARP (see Methods) as a reliable marker of apoptosis. Cells were treated for 24 hours as follows: pregnane glycoside MCF-7 20μM, MDA-MB-468 50 μM, Caco-2 10μM; androstan glycoside MCF7 12.5μM, MDA-MB-468 50μM, Caco-2 6.25μM. response to pregnane or androstan glycosides was confirmed with the use of Z-VAD-FMK. Furthermore, neither steroidal glycoside had an effect on DNA fragmentation in HUVEC or U937 cells (Fig. 9) .
MCF-7 Cells
MDA MB-468 from that study and our own.
We have begun to characterise the activity and the possible mechanisms of action of the pregnane and androstan glycosides isolated in this study. All of the measures of cytotoxic activity (MTT, NRU, DAPI, PARP cleavage, DNA ladder) on MCF-7, MDA MB-468 and Caco-2 cells were inhibited by pretreatment with the pan-caspase inhibitor Z-VAD-FMK. Our experiments therefore clearly showed that the pregnane and the androstan glycosides induced caspase-dependent apoptosis in MCF-7 and Caco-2 cells, while the MDA MB-468 cells were less sensitive. Interestingly, HUVEC and U937 cells were less affected by the pregnane and andostan glycosides, at least with regard to DNA fragmentation, the assay used to assess their effect. Possibly, the glycosides may show some selectively between malignant and normal cells, but further work is necessary. It is also presumed that the glycoside is cleaved by cell surface enzymes, such as lactase phorizin hydrolase, to allow the steroid to cross the plasma membrane and enter the cell.
Caspases are calcium-dependent enzymes activated via two basic pathways, extrinsic (e.g. ligation of socalled cell surface death receptors), or intrinsic (e.g. damage to mitochrondria), with caspase 3 particularly important in triggering cleavage of PARP and DNA fragmentation, both of which were end points detected in our experiments. Once PARP is cleaved, the cell is irreversibly committed to apoptosis. Pregnane glycosides are structurally similar to cardiac glycosides such as digoxin (Deepak et al 1997) , which inhibit calcium exchangers, thereby leading to a prolonged increase in intracellular calcium concentration and stimulation of caspases and apoptosis. Another possible mechanism of action is the activation of the steroid and xenobiotic receptor (SXR), an orphan steroid receptor, which induces apoptosis in breast cancer cells (Verma et al 2009) . Further studies are required, but the activation of the SXR is an exciting possibility.
The steroidal glycosides isolated in this study are novel but have some similarity to compound 46 Boucerosia aucheriana and Caralluma tuberculata which is part of the Asclepiadaceae family (Deepak et al 1991) , but no activity on tumour cells has been reported, so a comparison with our data is not possible.
Importantly, the pregnane glycoside (compound 1) we report here shares the structural skeleton of a synthetic aromatase inhibitor (compound 4a, Cepa et al 2008) and thus suggests aromatase inhibition as another possible mode of action of compound 1 to be investigated.
